Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice

International Journal of Cancer

Volumn 118, Issue 10, 2006, Pages 2514-2521

  McCarthy, Corinna ^a   Youde, Sarah J ^b   Man, Stephen ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cervical cancer; Cross reactivity; CTL; Epitope; HPV

Indexed keywords

DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; HLA ANTIGEN; HLA DB ANTIGEN; HLA KB ANTIGEN; PLASMID DNA; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; UTERINE CERVIX CANCER; VIRUS TYPING;

ANIMALS; ANTIBODY FORMATION; CROSS REACTIONS; DNA-BINDING PROTEINS; EPITOPES; FEMALE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMAN PAPILLOMAVIRUS 18; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VIRAL VACCINES;

EID: 33646409289     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21643     Document Type: Article

References (58)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. Shah KV. Do human papillomavirus infections cause oral cancer? J Natl Cancer Inst 1998;90:1585-86.
3. Kiviat NB. Papillomaviruses in non-melanoma skin cancer: epidemiological aspects. Semin Cancer Biol 1999;9:397-403.
4. Boyle P. Global burden of cancer. Lancet 1997;349(Suppl II):23-6.
5. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
6. Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, Glaubitz M, Niesert S, Kuhnle H, Schedel I. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994;57:836-40.
7. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251-8.
8. Stanley M, Coleman N, Chambers M. The host response to lesions induced by human papillomavirus. Ciba Found Symp 1994;187:21-44.
9. Zinkernagel RM. Immunology taught by viruses. Science 1996;271:173-8.
10. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995;1:1297-302.
11. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995;1:1179-83.
12. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castromalaspina H, Childs BH, Gillio AP, Small TN, Young JW, Keman NA, et al. Infusions of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994;330:1185-91.
13. Rooney CM, Smith CA, Ng CY, Loftin S, Li CF, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related-lymphoproliferation. Lancet 1995;345:9-13.
14. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
15. Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 1992;52:1-123.
16. zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994;48:427-47.
17. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV, International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
18. Tindle RW. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 1996;8:642-50.
19. van der Burg SH, de Jong A, Welters MJ, Offringa R, Melief CJ. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002;89:275-84.
20. Castellsague X, Menendez C, Loscertales MP, Kornegay JR, dos Santos F, Gomez-Olive FX, Lloveras B, Abarca N, Vaz N, Barreto A, Bosch FX, Alonso P. Human papillomavirus genotypes in rural Mozambique. Lancet 2001;358:1429-30.
21. Leachman SA, Brandsma JL. DNA vaccines for papillomavirus infections. In: Tindle RW, ed. Vaccines for human papillomavirus infection and anogenital disease. Austin: RG Landes Company, 1999. 105-48.
22. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
23. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999;6:1972-81.
24. Velders M, Weijzen S, Eiben G, Elmishad A, Kloetzel P, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast W. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001;166:5366-73.
25. Man S, Newberg MH, Crotzer VL, Luckey CJ, Williams NS, Chen Y, Huczko EL, Ridge JP, Engelhard VH. Definition of a human T cell epitope from influenza A non-structural protein using HLA-A2.1 transgenic mice. Int Immunol 1995;7:597-605.
26. Shirai M, Arichi T, Nishioka M, Nomura T, Ikeda K, Kawanishi K, Engelhard VH, Feinstone SM, Berzofsky JA. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995;154:2733-42.
27. Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel ML, Jack RW, Jung G, Kosmatopoulos K, Mateo L, Suhrbier A, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999;29:3112-21.
28. Butterfield L, Koh A, Meng W, Vollmer C, Ribas A, Dissette V, Lee E, Glaspy J, McBride W, Economou J. Generation of human T cell responses to an HLA-A2.1-restricted peptide epitope derived from a-fetoprotein. Cancer Res 1999;59:3134-42.
29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med 2003;348:518-27.
30. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
31. Faulkner L, Borysiewicz LK, Man S. The use of human leucocyte antigen class I transgenic mice to investigate human immune function. J Immunol Methods 1998;221:1-16.
32. Gotch F, Rothbard J, Howland K, Townsend A, McMichael AJ. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987;326:881-2.
33. Feltkamp MCW, Smits HL, Vierboom MPM, Minaar RM, de Jough BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast MW. Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
34. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-72.
35. Townsend A, Öhlén C, Bastin J, Ljunggren HG, Foster L, Kärre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1999;340:443-8.
36. Cerundolo V, Alexander J, Anderson K, Lamb C, Cresswell P, McMichael A, Gotch F, Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990;345:449-52.
37. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J Exp Med 1994;179:1109-18.
38. Tabi Z, Moutaftsi M, Borysiewicz LK. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J Immunol 2001;166:5695-703.
39. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus- specific cytotoxic T-lymphocytes. Cancer Res 1997;57:2943-50.
40. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004;78:8468-76.
41. + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42.
42. Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel ML, Jack R, Jung W, Kosmatopoulos K, Mateo L, Suhrbier A, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumour immunotherapeutic strategies. Eur J Immunol 1999;29:3112-21.
43. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR, Kast WM. Establishment of an HLA-A*0201 human papillomavirus type 16 tumour model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002;62:5792-9.
44. + T cells with genuine class I restriction. Eur J Immunol 1992;22:875-8.
45. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-342.
46. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox A, Appella E, Engelhard VH. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-3.
47. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
48. Rammensee H-G, Bachmann J, Emnierich N, Bachor O, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-19.
49. Rudolf MP, Man S, Melief CJ, Sette A, Kast WM. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001;7:788s-95s.
50. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio M-F, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92.
51. Braud VM, McMichael AJ, Cerundolo V. Differential processing of influenza nucleoprotein in human and mouse cells. Eur J Immunol 1998;28:625-35.
52. Street MD, Doan T, Herd KA, Tindle RW. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology 2002;106:526-36.
53. Sadovnikova E, Zhu X, Collins SM, Zhou J, Vousden K, Crawford L, Beverley P, Stauss H. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 1994;6:289-96.
54. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, et al. Immunization with human papillomavirus type 16(HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998;58:724-31.
55. Yoon H, Chung MK, Min SS, Lee HG, Yoo WD, Chung KT, Jung NP, Park SN. Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors. Virus Res 1998;54:23-9.
56. Kather A, Ferrara A, Nonn M, Schinz M, Nieland J, Schneider A, Durst M, Kaufmann AM. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Int J Cancer 2003;104:345-53.
57. Velders M, Weijzen S, Eiben G, Elmishad A, Kloetzel P, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001;166:5366-73.
58. Osen W, Peiler T, Ohlschlager P, Caldeira S, Faath S, Michel N, Muller M, Tomasino M, Jochmus I, Gissman L. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001;19:4276-86.